RxDoctor Payments Data

Jason Cook, MD

Vascular Surgery · Omaha, NENPI 1558742486

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,447 of the $7,302 with a category attached, or 74.6%. 11 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 37.4% of the total. Reporting peaked in 2019 at $2,450 and has fallen 87.2% since, to $313 in 2025.

$7,302in general payments, 2019–2025

Across 84 payments — averaging $86.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$3K
  • Inari Medical, Inc.$2K
  • Penumbra, Inc.$797
  • Medtronic$733
  • Cook Medical LLC$407
  • Shockwave Medical, Inc$257
  • plus $653 from 5 others

What the payments were for

  • Grants$5538%
  • Travel & lodging$98714%
  • Food & beverage$5,44775%
  • Education$3154%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,302 in reported general payments places this provider in the 65th percentile of 35 vascular surgery providers in Nebraska.

See all vascular surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$117,564
Medicare patients
629
Services billed
1,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban41$41,859
EliquisApixaban14$11,401
Atorvastatin Calcium125$741
ClopidogrelClopidogrel Bisulfate67$357
Cilostazol18$237
Gabapentin13$145
Prasugrel Hcl12$116
Pantoprazole Sodium12$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$250$41,85941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 35 vascular surgery providers in Nebraska.

Other vascular surgery in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →